Founded in 1960, the University of California, San Diego is one of the nation’s most accomplished research universities, widely acknowledged for its local impact, national influence and global reach. The campus is ideally located near the Pacific Ocean, the U.S.-Mexico border and the Pacific Rim. UC San Diego is renowned for its collaborative, diverse and cross-disciplinary ethos that transcends traditional boundaries in science, arts and the humanities. The university’s award-winning scholars are experts at the forefront of their fields with an impressive track record for achieving scientific, medical and technological breakthroughs. A leader in climate science research, UC San Diego is one of the greenest universities in the nation and promotes sustainability solutions throughout the region and the world.
Featured Startups and Technologies
Ortiva Wireless offers the industry’s most advanced commercial solutions for proactive management of mobile video, allowing service providers to dramatically improve control, quality, and efficiency of rich media content delivery. Ortiva’s mVOG (mobile Video Optimization Gateway) for portal services and iVOG (internet Video Optimization Gateway) for open internet media extend service reach, increase network efficiency, and improve video coverage density for mobile operators, while dynamically shaping the content to give subscribers the smoothest video and clearest audio experience possible — regardless of fluctuating and hostile wireless network conditions. Ortiva Wireless was founded in 2004 by Dr. Sujit Dey, based on innovative technologies developed at the University of California, San Diego, where he is a professor and heads the Mobile Systems Design and Test Laboratory. To learn more about how Ortiva is accelerating mobile video delivery, visit www.ortivawireless.com . NOTE: Ortiva, mVOG, and iVOG are trademarks of Ortiva Wireless, Inc. All other registered or unregistered trademarks are the sole property of their respective owners.
Senomyx is using proprietary taste receptor-based technologies to discover and develop novel flavor ingredients. As of September 30, 2010, the Company is the owner or exclusive licensee of 216 issued patents and several hundred pending patent applications related to taste receptor sequences and functions, screening assays, new flavor ingredients, and product applications. Senomyx’s discovery and development programs are focused on creating new flavor ingredients that enhance savory, sweet, salty, and cooling tastes, as well as ingredients that block bitter taste. Eight Senomyx flavor ingredients have received regulatory approvals, including S6973, a new sucrose enhancer that enables the reduction of up to 50% of the sugar in products while retaining the desired sweet taste. Senomyx has collaborations with six leading food, beverage, and ingredient companies: Nestlé, Campbell Soup, PepsiCo, Firmenich, Ajinomoto, and Solae, some of which are marketing products that contain Senomyx flavor ingredients.
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.
The company’s lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus. Over 325 people have received CMX001 to date, including more than 200 patients and healthy volunteers in ongoing placebo-controlled studies, and more than 125 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment. CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound’s antiviral activity in humans. To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. Chimerix is also developing CMX001 as a medical countermeasure in the event of a smallpox release.
Chimerix’s second clinical-stage antiviral compound, CMX157, has completed Phase 1 clinical studies. CMX157 is in development as a potent nucleoside analogue against multi-drug resistant HIV infections.
Led by a world-class antiviral drug development team, Chimerix is also leveraging the company’s extensive chemical library to pursue new treatments for hepatitis C virus, flu, dengue fever, malaria and other global public health needs. For additional information on Chimerix, please visit http://www.chimerix.com.
SciVee is the leading video platform solutions provider to the scientific, technical and medical market. SciVee provides a video publishing, distribution and hosting platform that enlivens the online presence of STM content providers. Its services drive higher traffic, increase viewers, promote authors, and generate new services and monetization options for publishers, societies, research and academic institutions. SciVee makes science visible. Our products and services are based on 5 elements:
- Browser-based synchronization technology (patent-pending), where a video and document are synchronized directly on the SciVee site.
- Software as a Service, so the customer does not need to invest in new software or worry about IT administration.
- A DIY (do it yourself) model, such that authors can create and upload videos quickly, easily and cheaply with minimal help from editors, publishers or SciVee.
- Easy integration into current production workflows of publishers and other content providers.
- A public website that is open for users to access and researchers to upload videos of interest, and a distribution option for publishers and other content providers.
Above all, we provide significant value to our users and customers in order to sustain long-term success. Founded in 2007, SciVee is headquartered in San Diego, CA, USA. Please visit www.scivee.tv for more information.